tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AtriCure price target raised to $54 from $52 at BTIG

BTIG raised the firm’s price target on AtriCure (ATRC) to $54 from $52 and keeps a Buy rating on the shares. The company reported a “wow” quarter, exceeding expectations on the top and bottom as revenue growth accelerated to 16.5%, with results driven by new product launches across the Pain and Appendage Management franchises, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1